By Michele Maatouk
Date: Wednesday 07 Jan 2026
(Sharecast News) - Ventyx Biosciences surged in pre-market trade on Wednesday following a report that Eli Lilly & Co. is in advanced talks to buy the company for more than $1bn to expand its work in immunology.
| Currency | US Dollars |
| Share Price | $ 1,108.09 |
| Change Today | $ 44.05 |
| % Change | 4.14 % |
| 52 Week High | $1,117.66 |
| 52 Week Low | $625.65 |
| Volume | 4,652,471 |
| Shares Issued | 948.17m |
| Market Cap | $1,050,658m |
| Beta | 0.69 |
| RiskGrade | 179 |
| Strong Buy | 12 |
| Buy | 12 |
| Neutral | 7 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 31 |

| Time | Volume / Share Price |
| 15:59 | 86 @ $1,108.14 |
| 15:59 | 40 @ $1,108.15 |
| 15:59 | 40 @ $1,108.14 |
| 15:59 | 77 @ $1,108.15 |
| 15:59 | 54 @ $1,108.13 |
You are here: research